Structural insights into human ABCC4 mediated transport of platelet agonist and inhibitor

The activation and accumulation of human platelets contributes to hemostasis and thrombosis, the imbalance of which would cause cardiovascular diseases, an increasing threat to the global health. Human ABC transporter ABCC4 that pumps out the platelet agonist and anti-platelet drug such as aspirin, might become a promising target for preventing cardiovascular diseases. Here we solve the structures of human ABCC4 in the apo and two complexed forms, all of which adopt a typical architecture of type-IV ABC transporters in an inward-facing conformation. Structure of ABCC4 complexed with U46619, an analog of the unstable TXA2, provides the first structural evidence that the platelet agonist TXA2 is also exported via ABCC4. The dipyridamole-complexed structure reveals the inhibitory mechanism of dipyridamole against ABCC4. Structural comparisons enabled us to identify a transmembrane pocket in ABCC4 that provides a defined space for the rational design of specific anti-platelet drugs.

[1]  Cong-Zhao Zhou,et al.  Structural basis of substrate recognition and translocation by human very long-chain fatty acid transporter ABCD1 , 2022, Nature Communications.

[2]  R. Allikmets,et al.  The human ATP‐binding cassette (ABC) transporter superfamily , 2022, Human mutation.

[3]  Cong-Zhao Zhou,et al.  Structures of human bile acid exporter ABCB11 reveal a transport mechanism facilitated by two tandem substrate-binding pockets , 2022, Cell Research.

[4]  R. Tampé,et al.  Structural and Mechanistic Principles of ABC Transporters. , 2020, Annual review of biochemistry.

[5]  Jue Chen,et al.  ATP Binding Enables Substrate Release from Multidrug Resistance Protein 1 , 2018, Cell.

[6]  Jue Chen,et al.  Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1 , 2017, Cell.

[7]  J. Schuetz,et al.  The ABCC4 membrane transporter modulates platelet aggregation. , 2015, Blood.

[8]  G. Peters,et al.  Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine , 2014, SpringerPlus.

[9]  P. Kalinski Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.

[10]  C. Gaudio,et al.  Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. , 2011, Journal of the American College of Cardiology.

[11]  G. Davı̀,et al.  Platelet activation and atherothrombosis. , 2007, The New England journal of medicine.

[12]  H. Kusuhara,et al.  Involvement of MRP4 (ABCC4) in the Luminal Efflux of Ceftizoxime and Cefazolin in the Kidney , 2007, Molecular Pharmacology.

[13]  Yuichi Sugiyama,et al.  Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir , 2007, Molecular Pharmacology.

[14]  Yuichi Sugiyama,et al.  Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. , 2007, Journal of the American Society of Nephrology : JASN.

[15]  M. Huang,et al.  Topotecan is a substrate for multidrug resistance associated protein 4. , 2006, Current drug metabolism.

[16]  D. Keppler,et al.  Prostanoid transport by multidrug resistance protein 4 (MRP4/ABCC4) localized in tissues of the human urogenital tract. , 2005, The Journal of urology.

[17]  H. Kroemer,et al.  The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. , 2004, Blood.

[18]  J. Wijnholds,et al.  The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Liqi Lai,et al.  Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. , 2002, The Biochemical journal.

[20]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[21]  Zhe-Sheng Chen,et al.  Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. , 2001, The Journal of biological chemistry.

[22]  A. Tsai,et al.  Substrate Binding Is the Rate-limiting Step in Thromboxane Synthase Catalysis* , 2001, The Journal of Biological Chemistry.

[23]  J. Lankelma,et al.  Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export , 2000, British Journal of Cancer.

[24]  D. Bell,et al.  Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. , 1998, Cancer research.

[25]  M. R. Alexander,et al.  Dipyridamole: A Critical Evaluation , 1984, Drug intelligence & clinical pharmacy.

[26]  J. M. Lipton,et al.  Analogs of endoperoxide precursors of prostaglandins: failure to affect body temperature when injected into primary and secondary central temperature controls. , 1977, Prostaglandins.

[27]  J. Ambrus,et al.  Critical evaluation. , 1965, The Wistar Institute symposium monograph.